| Outcome Measures: |
Primary: Maximum plasma concentration (Cmax) of SAR342434, US-approved Humalog and EU-approved Humalog, 12 hours|Area under the concentration versus time curve (AUC) of SAR342434, US-approved Humalog and EU-approved Humalog, 12 hours|Area under the body weight standardized glucose infusion rate (GIR) versus time curve from 0 to 12 hours post administration (GIR-AUC0-12), 12 hours | Secondary: The fractional area under the concentration versus time curve from 0 or y to x hours post administration (INS-AUC0 or Y to X), 12 hours|Time to 20% of AUC (t20%-AUC), 12 hours|NS-tmax, INS-t1/2z, 12 hours|The fractional area under the body weight standardized GIR versus time curve from 0 or y to x hours post administration (GIR-AUC0 or Y to X), 12 hours|Time to 20% of total GIR-AUC0-12h (t20%-GIR-AUC0-12h), 12 hours|Maximum smoothed body weight standardized GIR (GIRmax), 12 hours|Time to GIRmax (GIR-tmax), 12 hours|Duration of blood glucose control (time to elevation of smoothed blood glucose profile above clamp level and to elevation above different pre-specified blood glucose levels), 12 hours|Number of patients with AEs, SAEs, laboratory, vital signs and electrocardiographic abnormalities , injections site reaction assessment (ISR), and if any, hypoglycemia, 8 weeks
|
